HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
zeniplatin
structure given in first source
Also Known As:
(2,2-bis(aminomethyl)-1,3-propanediol-N,N')(1,1-cyclobutanedicarboxylato(2')-O,O')platinum(II); CL 286,558; CL 286558; CL-286558; CL286558
Networked:
6
relevant articles (
0
outcomes,
5
trials/studies)
Bio-Agent Context: Research Results
Organic Chemicals: 133
Coordination Complexes: 576
Carboplatin: 10368
zeniplatin: 6
Related Diseases
1.
Ovarian Neoplasms (Ovarian Cancer)
01/01/1993 - "
Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex.
"
01/01/1993 - "
Unfortunately, although we have defined definite but modest activity for zeniplatin in platinum-refractory ovarian cancer, further development of this drug has been discontinued because of the severe renal toxicity observed in other clinical trials of this cytotoxic agent.
"
01/01/1993 - "
Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy.
"
01/01/1993 - "
25 patients with residual or recurrent ovarian cancer were treated with the new platinum complex zeniplatin (CL 286,558) and 23 patients were evaluable for response.
"
01/01/1993 - "
A phase II trial of zeniplatin (CL 286,558), a third-generation platinum compound, was conducted in 31 patients with advanced ovarian cancer to examine the safety and activity of the agent when used as a salvage treatment in individuals previously exposed to organoplatinum-based therapy.
"
2.
Melanoma (Melanoma, Malignant)
02/01/1995 - "
A phase II trial of zeniplatin in metastatic melanoma.
"
02/01/1995 - "
Zeniplatin demonstrated only modest activity in melanoma with significant gastrointestinal and hematologic toxicity.
"
01/01/1997 - "
Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity.
"
01/01/1997 - "
The results show that zeniplatin has some activity (14%) in patients with advanced malignant melanoma, but no conclusion can be drawn regarding the activity of zeniplatin in renal cancer as the number of patients was too low.
"
01/01/1997 - "
Zeniplatin gave objective responses in 3 of the 21 evaluable malignant melanoma patients [2 complete responses (CRs) in patients with lymph-node metastases lasted 5 and 14 months, respectively; 1 partial response (PR) in a patient with lymph-node and liver metastases lasted 6 months].
"
3.
Kidney Neoplasms (Kidney Cancer)
01/01/1997 - "
Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity.
"
01/01/1997 - "
The results show that zeniplatin has some activity (14%) in patients with advanced malignant melanoma, but no conclusion can be drawn regarding the activity of zeniplatin in renal cancer as the number of patients was too low.
"
01/01/1997 - "
The antitumor activity of zeniplatin, a third-generation, water-soluble platinum compound that has shown broad preclinical antitumor activity and no significant nephrotoxicity in phase I trials, was tested in patients with advanced malignant melanoma and advanced renal cancer.
"
4.
Carcinoma (Carcinomatosis)
01/01/1995 - "
Zeniplatin, a more water-soluble organoplatinum than cisplatin, was evaluated for clinical pharmacology in the context of a phase II trial in previously treated patients with ovarian carcinoma.
"
5.
Vomiting
09/01/1991 - "
The most prominent non-hematological side-effect of zeniplatin was nausea and vomiting.
"
Related Drugs and Biologics
1.
Platinum
2.
zeniplatin
3.
Platinum Compounds (Compounds, Platinum)
4.
Cytotoxins (Cytolysins)
5.
Cisplatin (Platino)
Related Therapies and Procedures
1.
Therapeutics
2.
Salvage Therapy
3.
Drug Therapy (Chemotherapy)